Having trouble accessing articles? Reset your cache.

Forma’s $100M series D cements pivot from discovery shop to heme and cancer therapeutics

Forma’s $100 million in series D financing will fuel the company's push to join the wave of progress in sickle cell disease and complete its transformation from a chemistry research organization to a therapeutics company focused on blood disorders and cancer.

The financing is Forma

Read the full 445 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE